900210305 12/21/2011

TRADEMARK ASSIGNMENT

Electronic Version v1.1 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNS THE ENTIRE INTEREST AND THE GOODWILL

CONVEYING PARTY DATA

Name	Formerly	Execution Date	Entity Type
Lynrose Laboratories, LLC		111/02 <i> </i> 2011	LIMITED LIABILITY COMPANY: DELAWARE

RECEIVING PARTY DATA

Name:	Mission Pharmacal Company	
Street Address:	10999 Interstate Highway 10 West, Suite 1000	
City:	San Antonio	
State/Country:	TEXAS	
Postal Code:	78230-1355	
Entity Type:	CORPORATION: TEXAS	

PROPERTY NUMBERS Total: 1

Property Type	Number	Word Mark
Serial Number:	85251952	TEXACORT

CORRESPONDENCE DATA

 Fax Number:
 (770)744-1204

 Phone:
 770-744-1202 ext.247

 Email:
 khutton@staymacs.com

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent via US

Mail.

Correspondent Name: Kathryn Hutton
Address Line 1: P.O. Box 5607

Address Line 4: Alpharetta, GEORGIA 30023-5607

NAME OF SUBMITTER:	Kathryn Hutton
Signature:	/Kathryn Hutton/
Date:	12/21/2011

Total Attachments: 2

source=Trademark Assignment_Texacort_Lynrose_Mission#page1.tif source=Trademark Assignment_Texacort_Lynrose_Mission#page2.tif

TRADEMARK REEL: 004684 FRAME: 0540 OF \$40.00 85Z5185Z

ASSIGNMENT OF TRADEMARK

This ASSIGNMENT OF TRADEMARK (the "Assignment") is attached and incorporated into that Asset Purchase Agreement dated November 2, 2011, between Lynrose Laboratories, LLC, a Delaware limited liability company (the "Assignor") and Mission Pharmacal Company, a Texas corporation (the "Assignee").

WHEREAS, Assignor owns federal, state, and common law rights in the mark Texacort, U.S. Trademark Serial No. 85/251,952 (the "Mark"); and

WHEREAS, Assignee is desirous of acquiring Assignor's entire right, title, and interest in and to the Mark together with the goodwill of the business symbolized by the Mark in the U.S. and throughout the world, and the right to bring actions for past, present, or ongoing infringement of the Mark and recover of damages for any such infringement;

NOW, THEREFORE, effective as of November 2, 2011, and in consideration of monies paid and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged,

Assignor hereby sells, assigns and transfers to Assignee all of its rights, title and interest in and to the Mark, any and all common law rights to the Mark in the U.S. and any other location throughout the world, and the right to bring actions for past, present, or ongoing infringement and recovery of damages for any such infringement, together with the goodwill of the business connected with the use of and symbolized by the Mark and that portion of Assignor's business which pertains to the referenced intent-to-use application filed pursuant to Section 1(b) of the United States Trademark Act (15 U.S.C. §1051, et seq.); and

Assignor does hereby expressly agree that Assignee may undertake procedures to record the assignment of the Mark to the Assignee in the United State Patent and Trademark Office or to file an application to register a trademark for the Mark. Assignor shall execute and deliver such other documents and instruments, provide such materials and information and take such other actions as may reasonably be necessary, proper or advisable, to the extent permitted by law, to fulfill its obligations under this Assignment; and

Assignor hereby requests the Commissioner of Trademarks of the United States and any Official of any country or countries foreign to the U.S. whose duty is to receive or register trademarks or applications therefore to record Assignee as the owner of the Mark, and to issue all registrations for said Mark, to be in the name of Assignee, as assignee of the Mark, for the sole use of Assignee, its successors, legal representatives, and assigns, in accordance with the terms of this Assignment.

[remainder of page intentionally left blank]

1

IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed and delivered as of the day and year first above written.

LYNROSE LABORATORIES, LLC

MISSION PHARMACAL COMPANY

By: Web Henro

Name: Rick Henson

Title: President

Date: 730/11

Name: Thomas J. Dooley

Title: Chief Financial Officer

Date: 12/20/20//